ATE135690T1 - Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems - Google Patents

Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems

Info

Publication number
ATE135690T1
ATE135690T1 AT92901652T AT92901652T ATE135690T1 AT E135690 T1 ATE135690 T1 AT E135690T1 AT 92901652 T AT92901652 T AT 92901652T AT 92901652 T AT92901652 T AT 92901652T AT E135690 T1 ATE135690 T1 AT E135690T1
Authority
AT
Austria
Prior art keywords
nervous system
central nervous
agents
hydroxypiperidines
treatment
Prior art date
Application number
AT92901652T
Other languages
English (en)
Inventor
Shelly Glase
Juan Carlos Jaen
Sarah Jane Smith
Lawrence David Wise
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE135690T1 publication Critical patent/ATE135690T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT92901652T 1990-11-05 1991-10-29 Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems ATE135690T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60927490A 1990-11-05 1990-11-05
US07/778,248 US5273977A (en) 1990-11-05 1991-10-24 Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents

Publications (1)

Publication Number Publication Date
ATE135690T1 true ATE135690T1 (de) 1996-04-15

Family

ID=27085995

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92901652T ATE135690T1 (de) 1990-11-05 1991-10-29 Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems

Country Status (11)

Country Link
US (3) US5273977A (de)
EP (1) EP0556332B1 (de)
JP (1) JP3047470B2 (de)
AT (1) ATE135690T1 (de)
AU (1) AU670532B2 (de)
CA (1) CA2094702C (de)
DE (1) DE69118198T2 (de)
DK (1) DK0556332T3 (de)
ES (1) ES2084339T3 (de)
GR (1) GR3019782T3 (de)
WO (1) WO1992007831A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
DE4425145A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
GB9523462D0 (en) * 1995-11-16 1996-01-17 Merck Sharp & Dohme Therapeutic agents
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
CN1251577A (zh) * 1997-02-21 2000-04-26 武田药品工业株式会社 稠环化合物及其生产和应用
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
EP1200086A4 (de) * 1999-08-04 2009-05-27 Icagen Inc Methoden zur behandlung oder vorbeugung von schmerzen und angstzuständen
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
EP1208085B1 (de) * 1999-08-04 2007-12-05 Icagen, Inc. Benzanilide als öffner des kaliumkanals
HUP0204444A3 (en) * 1999-10-22 2004-07-28 Sanofi Aventis Phenyl- and pyridyl-tetrahydro-pyridines, process for their preparation and pharmaceutical compositions containing them
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
TWI450900B (zh) 2008-03-24 2014-09-01 Medivation Technologies Inc 橋聯雜環化合物及使用方法
WO2011038161A1 (en) * 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
CN102711466A (zh) * 2009-09-23 2012-10-03 梅迪维新技术公司 桥连杂环化合物及其使用方法
CA3006745C (en) 2010-11-05 2021-03-30 Oat Agrio Co., Ltd. Ethynylphenylamidine compound or salt thereof, method for producing same, and fungicide for agricultural and horticultural use
CA2829045A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
CN106243088B (zh) 2015-06-03 2019-01-04 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633474A (de) *
GB1055548A (en) * 1965-08-23 1967-01-18 Acraf New substituted 1-aryl-3-aminopropynes and process for their preparation
FR1490501A (fr) * 1966-02-23 1967-08-04 Docteur Jacques Auciair Lab Du Nouveaux dérivés du butyne-2 et leur procédé de préparation
US4208415A (en) * 1978-02-06 1980-06-17 E. R. Squibb & Sons, Inc. 4-[2-(2-Substituted phenyl)ethenyl]-N-alkenyl or alkinyl substituted 1,2,3,6-tetrahydropyridines
AU593194B2 (en) * 1986-09-26 1990-02-01 Sumitomo Pharmaceuticals Company, Limited Imide derivatives ,and their production and use
CA2071897A1 (en) * 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
US5034392A (en) * 1990-04-16 1991-07-23 Hoechst-Roussel Pharmaceuticals Incorporated 4-(3-(4-oxothiazolidinyl)butynylamines
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents

Also Published As

Publication number Publication date
EP0556332B1 (de) 1996-03-20
ES2084339T3 (es) 1996-05-01
EP0556332A1 (de) 1993-08-25
DE69118198T2 (de) 1996-11-14
AU9123191A (en) 1992-05-26
JP3047470B2 (ja) 2000-05-29
JPH06501952A (ja) 1994-03-03
US5466698A (en) 1995-11-14
WO1992007831A1 (en) 1992-05-14
US5620988A (en) 1997-04-15
DE69118198D1 (de) 1996-04-25
AU670532B2 (en) 1996-07-25
GR3019782T3 (en) 1996-07-31
US5273977A (en) 1993-12-28
DK0556332T3 (da) 1996-06-03
CA2094702C (en) 2002-02-12
CA2094702A1 (en) 1992-05-06

Similar Documents

Publication Publication Date Title
DE69118198D1 (de) Substituierte tetrahydropyridine und hydroxypiperidine als mittel zur behandlung des zentralen nervensystems
MY107728A (en) Substituted cyclohexanols as central nervous system agents.
BG100830A (en) Naphthylamides as central nervous system agents
TR199900255T2 (xx) Muskarinik antagonistleri
ATE418986T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems welche einen nicotin-analog und einen acetylcholinesterase inhibitor enthalten
NO961687D0 (no) Nye (R)-5-karbamoyl-8-fluor-3-N,N-disubstituerte-amino-3,4-dihydro-2H-1-benzopyraner
NO180632C (no) 1,3-substituerte cykloalkener og cykloalkaner som sentralnervesystem-midler
ATE132855T1 (de) Substituierte piperazine als mittel zur behandlung des zentrallen nervensystems
MY107354A (en) Substituted cyclohexenes as central nervous system agents
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
MX9302225A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee